US20050196782A1 - Universal amplification of fragmented RNA - Google Patents
Universal amplification of fragmented RNA Download PDFInfo
- Publication number
- US20050196782A1 US20050196782A1 US11/020,946 US2094604A US2005196782A1 US 20050196782 A1 US20050196782 A1 US 20050196782A1 US 2094604 A US2094604 A US 2094604A US 2005196782 A1 US2005196782 A1 US 2005196782A1
- Authority
- US
- United States
- Prior art keywords
- rna
- cdna
- cancer
- reverse
- pcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
Definitions
- the present invention relates to methods of preparing RNA for gene expression profiling by a variety of methods.
- the methods of the invention are particularly useful for universal amplification of RNA, including RNA in which one or more RNA species is fragmented and/or blocked at it 3′ terminus, such as is obtained from fixed paraffin-embedded tissue (FPET).
- FPET fixed paraffin-embedded tissue
- the methods are also useful for detecting RNA species which lack polyadenylation.
- methods of enhanced RT-PCR for useful in gene expression profiling are provided.
- Gene expression profiling is increasingly important both in biological research and in clinical practice. Gene expression profiling has been used to classify various cancer types (see, e.g. Golub et al., Science 286:531-537 (1999); Bhattacharjae et al., Proc. Natl. Acad. Sci. USA 98:13790-13795 (2001); Chen-Hsiang et al., Bioinformatics 17 (Suppl. 1):S316-S322 (2001); Ramaswamy et al., Proc. Natl. Acad. Sci. USA 98:15149-15154 (2001); Martin et al., Cancer Res. 60:2232-2238 (2000); West et al., Proc. Natl.
- antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes.
- duplexes including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes.
- RNA cannot serve as a template for PCR
- the first step in gene expression profiling by RT-PCR is the reverse transcription of the RNA template into cDNA, followed by its exponential amplification in a PCR reaction.
- the conversion of mRNA to cDNA is typically performed by oligo dT priming of the mRNA in the presence of the reverse transcriptase (RT) enzyme.
- RT reverse transcriptase
- FPET samples are the most widely available source of RNA for gene expression profiling in clinical oncology and because archived FPET samples are an important source of RNA for gene expression profiling in research oncology, there is a critical need for methods that enable and improve the efficacy of gene expression profiling using such tissue samples.
- the present invention provides a sample preparation method that enables global amplification of even very small or very fragmented RNA samples.
- the method of the invention improve the sensitivity of RNA analysis methods, including RT-PCR and hybridization arrays.
- the methods of the invention permit the measurement of mRNA levels of all expressed genes including fragmented and/or blocked mRNA species in archived paraffin-embedded tissue samples.
- This method also permits the measurement of non-polyadenylated mRNA such as histones and non-coding RNAs, such as microRNAs (miRNAs).
- the invention may additionally include an enhanced reverse transcription step and a modified PCR step that increases the sensitivity of RT-PCR used for gene expression profiling of fragmented RNA samples.
- the invention concerns a method for preparing a multiplicity of RNA species, which may include fragmented and/or blocked RNA species, for gene expression analysis comprising the steps of:
- the size of the RNA species within the fragmented RNA is between about 20 bases and about 2000 bases, more frequently between about 50 and about 300 bases.
- Polyadenylation can, for example, be performed with E. coli polyA polymerase.
- the method of the invention may additionally include a step of deblocking.
- Deblocking can be performed by using conventional reagents, such as, for example, with a phosphatase enzyme, e.g. calf alkaline phosphatase (CIP), bacterial alkaline phosphatase, shrimp alkaline phosphatase, or variants thereof, or with a polynucleotide kinase (PNK), e.g. T4 polynucleotide kinase (T4 PNK), or variants thereof.
- a phosphatase enzyme e.g. calf alkaline phosphatase (CIP), bacterial alkaline phosphatase, shrimp alkaline phosphatase, or variants thereof
- PNK polynucleotide kinase
- T4 PNK T4 polynucleotide kinase
- the polyadenylated fragmented RNA obtained in step (a) above is converted to cDNA by treatment with a reverse transcriptase and oligo-dT primers, where the oligo-dT primers may optionally contain an RNA polymerase promoter (e.g. T7 RNA polymerase promoter) sequence.
- a reverse transcriptase and oligo-dT primers may optionally contain an RNA polymerase promoter (e.g. T7 RNA polymerase promoter) sequence.
- the polyadenylating agent such as CIP, or PNK, is removed.
- the polyadenylated fragmented RNA is converted to cDNA without prior removal of the polyadenylating agent, such as CIP, or PNK.
- the polyadenylated fragmented RNA is enriched, e.g. by removal of rRNA sequences, prior to conversion to cDNA and subsequently to double-stranded cDNA.
- the polyadenylated fragmented RNA is immobilized before conversion to a cDNA.
- the polyadenylated fragmented RNA is hybridized to a solid phase bead format.
- the immobilized polyadenylated fragmented RNA is enriched prior to conversion to cDNA.
- the enrichment may comprise removal of rRNA sequences by hybridization to bead immobilized complementary rRNA oligonucleotides.
- the RNA is mRNA obtained from a fixed, paraffin-embedded tissue sample, such as a tumor sample, where the tumor may be cancer, such as, for example, breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, or brain cancer.
- cancer such as, for example, breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, or brain cancer.
- the method of the invention may additional comprise the step of (c) PCR amplification using one or more cDNA species present in the cDNA obtained in step (b) above as a template.
- PCR amplification comprises about 40 cycles, of which the first five cycles, or the first two to five cycles, or the first two cycles are performed at a lower annealing/extension temperature, such as, at a temperature of about 40° C. to 58° C., e.g. about 50° C.
- the method of the invention further comprises the steps of:
- the polyadenylated fragmented RNA obtained in step (a) is converted to cDNA by treatment with a reverse transcriptase and extended reverse primers, and the cDNA obtained is amplified by PCR using a forward and a reverse PCR primer and a probe, designed based on a target amplicon.
- the invention concerns a method for enhanced cDNA synthesis, comprising converting RNA to cDNA by treatment with a reverse transcriptase and extended primers, and amplifying the cDNA obtained by PCR using a forward and a reverse PCR primer and a probe, designed based on a target amplicon.
- the RNA may be fragmented, at least part of which may be non-polyadenylated.
- the invention concerns a method for preparing RNA comprising a multiplicity of RNA species for gene expression analysis comprising the steps of:
- the invention concerns a method for preparing RNA comprising a multiplicity of RNA species for gene expression analysis comprising the steps of:
- FIG. 1 is a chart illustrating the overall workflow of the amplification process in the invention used for measuring gene expression.
- FPET stands for “fixed paraffin-embedded tissue
- PNK stands for “polynucleotide kinase”
- CIP stands for “calf intestinal alkaline phosphatase”
- EPAP stands for “ E. coli polyA polymerase”
- TdT stands for “Terminal Transferase”
- IVT stands for “in vitro transcription”
- rNTP stands for “ribonucleoside-5′-triphosphate”
- dNTP stands for “2′-deoxyribonucleoside-5′-triphosphate”
- ATP stands for “adenosine-5′-triphosphate”.
- T7-(T) 24 is a primer for cDNA synthesis using reverse transcriptase and stands for T7 RNA polymerase promoter sequence attached to the 5′end of polydeoxyadenylate.
- T7-(N)15 is a primer for cDNA synthesis using reverse transcriptase and stands for T7 RNA polymerase promoter sequence attached to the 5′ end of a random deoxy-pentadecamer.
- FIG. 1 there are three representative protocols (A, B and C) of the invention.
- Processes A and B start with FPET RNA and involve 1) direct or indirect unblocking of the 3′OH on the terminal nucleotide, 2) poly A tailing of the 3′ end, 3) oligo dT-primed double-strand cDNA synthesis with the incorporation of a T7 RNA polymerase promoter, and 4) RNA amplification by in vitro transcription.
- Process C (middle of diagram) starts with FPET RNA and involves 1) directly synthesizing double-stranded cDNA using T7-(N)15 primers with a T7 RNA polymerase promoter, and 2) RNA amplification by in vitro transcription.
- FIG. 2 shows a gel image of FPET RNA isolated from twelve different breast cancer patient's biopsies. Lanes M1 and M2 show RNA markers with the size of each band denoted in bases. Lanes 1-4, 5-8 and 9-12 are from tumor biopsies that have been archived for 1, 6 and 17 years respectively. Samples were analyzed by capillary electrophoresis on an Agilent 2100 Bioanalyzer using an RNA 6000 Nanochip.
- FIG. 3 shows selected gene expression analysis of breast tumor FPET RNA, randomly degraded breast tumor RNA and intact breast tumor RNA. Expression was analyzed by real time quantitative RT-PCR (TaqMan®) on an ABI Prism® 7700. cDNA synthesis was primed with either gene specific primers (GSP) or oligo (dT) 12-18 . Relative yields are measured by the threshold cycle (Ct).
- GSP gene specific primers
- dT oligo
- FIG. 4 shows a selected gene expression analysis of breast tumor FPET RNA. Expression was analyzed by real time quantitative RT-PCR (TaqMan®) on an ABI Prism® 7700. cDNA synthesis was primed with either GSPs or oligo (dT) 12-18 using template RNA that was not polyadenylated (FPET/GSP and FPET/dT) or cDNA synthesis was primed with oligo (dT) 12-18 using template RNA that was polyadenylated (FPET-pA/dT). Relative yields are measured by the threshold cycle (Ct).
- Ct threshold cycle
- FIG. 5 shows a gene expression analysis of in vitro transcribed cRNAs. Expression was analyzed by real time quantitative RT-PCR (TaqMan®) on an ABI Prism® 7700. RNA polyadenylation was performed with 0.2 units of EPAP and cDNA synthesis was performed as in FIG. 4 . See Materials and Methods for generating the template cRNA. Relative yields are measured by the threshold cycle (Ct). Inset: Agilent 2100 gel image of cRNAs treated with 0, 0.1 or 0.2 units of EPAP. Lane M shows RNA markers with the size of each band denoted in bases.
- FIG. 6A shows a gel image of FPET RNAs that have been treated with PNK (lane 1), PNK buffer control (lane 2), CIP (lane 3) or CIP buffer control (lane 4).
- FIG. 6B shows a gel image of FPET RNAs that have been treated with PNK buffer control followed by EPAP buffer control (lane 1), PNK followed by EPAP buffer control (lane 2), PNK buffer control followed by EPAP, or PNK followed by EPAP (lane 4).
- Samples were analyzed by capillary electrophoresis on an Agilent 2100 using an RNA 6000 Nanochip. Lanes M1 and M2 show RNA markers with the size of each band denoted in bases.
- FIG. 7 shows a selected gene expression analysis of breast tumor FPET RNA. Expression was analyzed by real time quantitative RT-PCR (TaqMan®) on an ABI Prism® 7700. Prior to gene expression analysis, the RNA was treated with PNK (+PNK) or buffer control ( ⁇ PNK), followed by polyadenylation by EPAP. The RNA was then converted into cDNA with reverse transcriptase and oligo dT primers (+PNK/Oligo dT and ⁇ PNK/Oligo dT) or gene specific primers (+PNK/GSP and ⁇ PNK/GSP). Relative yields are measured by the threshold cycle (Ct). Inset: Agilent 2100 gel image of FPET RNA treated with PNK or buffer control followed by EPAP. Lane M shows RNA markers with the size of each band denoted in bases.
- FIG. 8 shows selected gene expression analysis of breast tumor FPET RNA. Expression was analyzed by real time quantitative RT-PCR (TaqMan®) on an ABI Prism® 7700. Prior to gene expression analysis, the RNA was treated with CIP (+CIP) or buffer control ( ⁇ CIP), followed by polyadenylation by EPAP. The RNA was then converted into cDNA with reverse transcriptase and oligo dT primers (+CIP/Oligo dT and ⁇ CIP/Oligo dT) or gene specific primers (+CIP/GSP and ⁇ CIP/GSP). Relative yields are measured by the threshold cycle (Ct). Inset: Agilent 2100 gel image of FPET RNA treated with CIP or buffer control followed by EPAP. Lane M shows RNA markers with the size of each band denoted in bases.
- FIG. 9 shows a 96 gene panel expression analysis of breast tumor FPET RNA. Expression was analyzed by real time quantitative RT-PCR (TaqMan®) on an ABI Prism® 7900. Prior to gene expression analysis, the RNA was treated with PNK, followed by treatment with EPAP. The RNAs were then converted into cDNA with reverse transcriptase and oligo dT primers (pA_dT) or gene specific primers (pA_GSP1). Non-polyadenylated RNA was also converted to cDNA as above (untreated_dT and untreated GSP1). Relative yields are measured by the threshold cycle (Ct). Statistical analysis of the results are shown in Table 1.
- FIGS. 10 A-C show a 46 gene panel expression analysis of amplified and unamplified FPET RNA.
- Three different RNAs were profiled. Intact Universal total RNA (Stratagene, La Jolla, Calif.) is shown in FIG. 10A , placental FPET RNA (from placenta treated for 1.5-2 h with formalin and paraffin-embedded by BioPathology Sciences Medical Corporation, South San Francisco, Calif.) is shown in FIG. 10B and breast tumor FPET RNA (Clinomics BioSciences, Pittsfield, Mass.) is shown in FIG. 10C . Expression was analyzed by real time quantitative RT-PCR (TaqMan®) on an ABI Prism® 7900.
- RNA samples Prior to gene expression analysis, two separate samples of RNA were treated with PNK followed by EPAP and then converted into cDNA with reverse transcriptase and oligo dT-T7 primers.
- the cDNA was made double-stranded with DNA polymerase I and RNAseH, amplified by IVT [IVT (tailed-1) and IVT (tailed-2)] and then analyzed by TaqMan®
- IVT DNA polymerase I and RNAseH
- IVT IVT (tailed-1) and IVT (tailed-2)
- TaqMan® As a control, non PNK/nonEPAP-treated FPET RNA was converted to double-stranded cDNA and amplified by IVT [IVT (untailed)] as above or converted to cDNA by GSPs (GSP) prior to analysis by TaqMan®.
- Relative yields are measured by the threshold cycle (Ct).
- the inset tables show the overall average Ct of the 46 genes profile
- FIG. 11 is a scheme depicting the strategy for enhancing gene specific priming of fragmented FPET RNA.
- FPET stands for “fixed paraffin-embedded tissue
- Me Gppp refers to the 5′ methylated guanylate CAP structure of mRNA
- a 100-300 refers to the 3′ polyA tract of mRNA
- RT stands for reverse transcriptase
- PCR polymerase chain reaction
- amplicon stands for the region of the mRNA amplified by PCR
- GSP stands for gene specific primer.
- the extended reverse primers (10b, 20b and 30b) are identical to the reverse primer but extend roughly 10, 20 and 30 bases further into the amplicon.
- the 3′ of the 30b RT primer and the 3′ end of the forward primer are separated by a single base.
- FIG. 12 shows selected gene expression analysis of breast tumor FPET RNA (Clinomics 168). Expression was analyzed by real time quantitative RT-PCR (TaqMan®) on an ABI Prism® 7700. cDNA synthesis was primed with either gene specific primers (Std primers) or extended reverse primers (10b, 20b and 30b primers). Relative yields are measured by the threshold cycle (Ct).
- FIG. 13 is a schematic diagram illustrating the overall workflow of the improved, bead based amplification process in the invention used for measuring gene expression.
- FPET stands for “fixed paraffin-embedded tissue
- PNK stands for “polynucleotide kinase”
- EPAP stands for “ E.
- O-T7-(TTT) is a solid phase, immobilized primer for cDNA synthesis consisting of a T7 RNA polymerase promoter sequence and an oligodeoxythymidylate sequence attached to a magnetic polystyrene bead
- RT stands for “Reverse Transcriptase”
- RNAse H stands for “Ribonuclease H”
- DNA pol I stands for the “DNA polymerase I”
- IVT stands for “in vitro transcription”
- cRNA stands for “complementary RNA generated by IVT
- O-( ⁇ ) rRNA refers to bead immobilized complementary ribosomal RNA sequences (synthesized as short DNA oligos).
- the improved, bead based protocol is shown in the central portion of the diagram (solid arrows).
- the process starts with FPET RNA, generally 50-200 ng, and involves 1) unblocking of the 3′OH on the terminal nucleotide with PNK, 2) direct EPAP poly A tailing of the FPET RNA 3′ without cleanup from PNK step, 3) hybridization of polyadenylated FPET RNA to oligo dT-T7 RNA polymerase promoter sequences immobilized to beads followed by 4) cDNA synthesis with RT, 5) partial RNA degradation by RNAse H and second strand DNA synthesis with DNA polymerase I and 6) RNA amplification by in vitro transcription.
- An optional procedure for a second round of IVT is shown in step 7 (broken arrows).
- Another optional step, shown in step 2′ involves depletion of ribosomal rRNA fragments (dotted arrow).
- FIG. 14 shows the results from various PNK cleanup modifications followed by polyadenylation by EPAP.
- the left panel shows FPET RNA size by microcapillary electrophoresis using the Agilent 2100 Bioanalyzer. Lane descriptions: Ladder, RNA molecular weight markers from 200 bases (lowest) to 6000 bases; SM, unmodified FPET RNA. 1-6, PNK cleanup conditions described in the right panel.
- P/C refers to phenol/chloroform ; DEPC-30 column refers to CHROMA SPINTM DEPC-H 2 O 30 column, heat inactivation conditions were 65° C., 20 min. Percent recovery after EPAP cleanup is relative to input FPET RNA (1000 ng).
- FIG. 15 shows a 47 gene panel expression analysis of amplified breast tumor FPET RNA (Clinomics BioSciences, Pittsfield, Mass.). Expression was analyzed by real time quantitative RT-PCR (TaqMan®) on an ABI Prism® 7900. Relative yields are measured by the threshold cycle (Ct).
- the inset tables show the overall average Ct of the 47 genes profiled for each cleanup condition and the cRNA yield for each IVT. The cleanup conditions are described below in Example 2.
- FIG. 16 shows a 47 gene panel expression analysis of Placental FPET RNA amplified by a non-bead based (Free IVT) and a bead based (Solid Phase IVT) described in Example 3.
- SM unamplified starting material
- the placenta was treated for 1.5-2 h with formalin and paraffin-embedded by BioPathology Sciences Medical Corporation, South San Francisco, Calif.
- Expression was analyzed by real time quantitative RT-PCR (TaqMan®) on an ABI Prism® 7900.
- Relative yields are measured by the threshold cycle (Ct).
- the inset tables show the overall average Ct of the 47 genes profiled for each cleanup condition and the cRNA yield for each IVT. Also shown are yields after normalization (Yield;Ct. adj.).
- the equation for normalizing yields is: cRNA Yield/2 (Avg. Ct.-SM Ct.)
- FIGS. 17 A-C show a 47 gene panel expression analysis of amplified Placental FPET RNA.
- the placenta was treated for 1.5-2 h with formalin and paraffin-embedded by BioPathology Sciences Medical Corporation, South San Francisco, Calif. Expression was analyzed by real time quantitative RT-PCR (TaqMan®) on an ABI Prism® 7900. Relative yields are measured by the threshold cycle (Ct).
- the inset tables show the overall average Ct of the 47 genes profiled for each FRA condition and the cRNA yield for each IVT. The three FRA conditions are described below in Example 4.
- FIGS. 17A and 17B show the results from the primary and secondary amplification, respectively.
- FIG. 17C shows a comparison of a primary and secondary IVT (Condition 3).
- polyadenylation or “poly A tailing” refers to the addition of a stretch of adenylate molecules (poly (A)) to the 3′ end of RNA, e.g. mRNA.
- Blocking of polyadenylation or “blocked 3′ end” of RNA refers to blocking the availability of the 3′-terminal ribose moiety of RNA for a polyadenylation reaction. This may occur, for example, because the 3′ terminus of RNA contains various phosphate esters typically 2′-3′ cyclic phosphates, 2′-monophosphates and 3′-monophosphates which need to be removed to permit addition of a poly A tail to the 3′ terminus of the RNA.
- Dephosphorylation refers to the removal of phosphate esters (described above) by any methods, including but not limited to enzymatic techniques, such as using calf intestinal phosphatase (CIP) or T4 Polynucleotide Kinase (PNK).
- CIP calf intestinal phosphatase
- PNK T4 Polynucleotide Kinase
- “Threshold cycle (Ct)” refers to relative yields of nucleic acid amplified in a PCR reaction.
- the 5′-nuclease activity of the Taq polymerase is utilized to cleave and release a quenched reporter dye present on a third oligonucleotide primer (which is non-extendible by Taq polymerase) that detects a nucleotide sequence located between the two PCR primers.
- a third oligonucleotide primer which is non-extendible by Taq polymerase
- One molecule of reporter dye is liberated for each newly synthesized nucleic acid molecule and detection of this unquenched reporter dye provides the basis for quantitative interpretation of amplification or the mount of product amplified to that point in the amplification reaction.
- Ct threshold cycle
- microarray refers to an ordered arrangement of hybridizable array elements, such as polynucleotide probes, on a substrate.
- polynucleotide when used in singular or plural, generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
- polynucleotides as defined herein include, without limitation, single- and double-stranded DNA, DNA including single- and double-stranded regions, single- and double-stranded RNA, and RNA including single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or include single- and double-stranded regions.
- polynucleotide refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA.
- the strands in such regions may be from the same molecule or from different molecules.
- the regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules.
- One of the molecules of a triple-helical region often is an oligonucleotide.
- polynucleotide specifically includes DNAs and RNAs that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are “polynucleotides” as that term is intended herein.
- DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritiated bases are included within the term “polynucleotides” as defined herein.
- polynucleotide embraces all chemically, enzymatically and/or metabolically modified forms of unmodified polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells.
- oligonucleotide refers to a relatively short polynucleotide, including, without limitation, single-stranded deoxyribonucleotides, single- or double-stranded ribonucleotides, RNA:DNA hybrids and double-stranded DNAs. Oligonucleotides, such as single-stranded DNA probe oligonucleotides, are often synthesized by chemical methods, for example using automated oligonucleotide synthesizers that are commercially available. However, oligonucleotides can be made by a variety of other methods, including in vitro recombinant DNA-mediated techniques and by expression of DNAs in cells and organisms.
- differentially expressed gene refers to a gene whose expression is activated to a higher or lower level in a subject suffering from a disease, specifically cancer, such as breast cancer, relative to its expression in a normal or control subject.
- the terms also include genes whose expression is activated to a higher or lower level at different stages of the same disease. It is also understood that a differentially expressed gene may be either activated or inhibited at the nucleic acid level or protein level, or may be subject to alternative splicing to result in a different polypeptide product. Such differences may be evidenced by a change in mRNA levels, surface expression, secretion or other partitioning of a polypeptide, for example.
- Differential gene expression may include a comparison of expression between two or more genes, or a comparison of the ratios of the expression between two or more genes, or even a comparison of two differently processed products of the same gene, which differ between normal subjects and subjects suffering from a disease, specifically cancer, or between various stages of the same disease.
- Differential expression includes both quantitative, as well as qualitative, differences in the temporal or cellular expression pattern in a gene or its expression products among, for example, normal and diseased cells, or among cells which have undergone different disease events or disease stages.
- “differential gene expression” is considered to be present when there is at least about two-fold, preferably at least about four-fold, more preferably at least about six-fold, most preferably at least about ten-fold difference between the expression of a given gene in normal and diseased subjects, or in various stages of disease development in a diseased subject.
- gene amplification refers to a process by which multiple copies of a gene or gene fragment are formed in a particular cell or cell line.
- the duplicated region (a stretch of amplified DNA) is often referred to as “amplicon.”
- amplicon a stretch of amplified DNA
- the amount of the messenger RNA (mRNA) produced i.e., the level of gene expression, also increases in the proportion of the number of copies made of the particular gene expressed.
- splicing and “RNA splicing” are used interchangeably and refer to RNA processing that removes introns and joins exons to produce mature mRNA with continuous coding sequence that moves into the cytoplasm of an eukaryotic cell.
- exon refers to any segment of an interrupted gene that is represented in the mature RNA product (B. Lewin. Genes IV Cell Press, Cambridge Mass. 1990).
- intron refers to any segment of DNA that is transcribed but removed from within the transcript by splicing together the exons on either side of it. Operationally, exon sequences occur in the mRNA sequence of a gene as defined by Ref. Seq ID numbers. Operationally, intron sequences are the intervening sequences within the genomic DNA of a gene, bracketed by exon sequences and having GT and AG splice consensus sequences at their 5′ and 3′ boundaries.
- tumor refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
- cancer and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
- examples of cancer include but are not limited to, breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer.
- the “pathology” of cancer includes all phenomena that compromise the well-being of the patient. This includes, without limitation, abnormal or uncontrollable cell growth, metastasis, interference with the normal functioning of neighboring cells, release of cytokines or other secretory products at abnormal levels, suppression or aggravation of inflammatory or immunological response, etc.
- RT-PCR Real-Time Reverse Transcriptase PCR
- RT-PCR which can be used to compare mRNA levels in different sample populations, in normal and tumor tissues, with or without drug treatment, to characterize patterns of gene expression, to discriminate between closely related mRNAs, and to analyze RNA structure.
- the first step in gene expression profiling by RT-PCR is the reverse transcription of the RNA template into cDNA, followed by its exponential amplification in a PCR reaction.
- the two most commonly used reverse transcriptases are avian myeloblastosis virus reverse transcriptase (AMV-RT) and Moloney murine leukemia virus reverse transcriptase (MMLV-RT).
- AMV-RT avian myeloblastosis virus reverse transcriptase
- MMLV-RT Moloney murine leukemia virus reverse transcriptase
- the reverse transcription step is typically primed using gene specific primers, random hexamers, or oligo-dT primers, depending on the circumstances and the goal of expression profiling.
- extracted RNA can be reverse-transcribed using a GeneAmp RNA PCR kit (Perkin Elmer, Calif., USA), following the manufacturer's instructions.
- the derived cDNA can then be used as a template in the subsequent PCR reaction.
- the PCR step can use a variety of thermostable DNA-dependent DNA polymerases, it typically employs the Taq DNA polymerase, which has a 5′-3′ nuclease activity but lacks a 3′-5′ proofreading endonuclease activity.
- TaqMan® PCR typically utilizes the 5′-nuclease activity of Taq or Th polymerase to hydrolyze a hybridization probe bound to its target amplicon, but any enzyme with equivalent 5′ nuclease activity can be used.
- Two oligonucleotide primers are used to generate an amplicon typical of a PCR reaction.
- a third oligonucleotide, or probe is designed to detect nucleotide sequence located between the two PCR primers.
- the probe is non-extendible by Taq DNA polymerase enzyme, and is labeled with a reporter fluorescent dye and a quencher fluorescent dye. Any laser-induced emission from the reporter dye is quenched by the quenching dye when the two dyes are located close together as they are on the probe.
- the Taq DNA polymerase enzyme cleaves the probe in a template-dependent manner.
- the resultant probe fragments disassociate in solution, and signal from the released reporter dye is free from the quenching effect of the second fluorophore.
- One molecule of reporter dye is liberated for each new molecule synthesized, and detection of the unquenched reporter dye provides the basis for quantitative interpretation of the data.
- TaqMan® RT-PCR can be performed using commercially available equipment, such as, for example, ABI PRISM 7700TM Sequence Detection SystemTM (Perkin-Elmer-Applied Biosystems, Foster City, Calif., USA), or Lightcycler (Roche Molecular Biochemicals, Mannheim, Germany).
- the 5′ nuclease procedure is run on a real-time quantitative PCR device such as the ABI PRISM 7700TM Sequence Detection SystemTM.
- the system consists of a thermocycler, laser, charge-coupled device (CCD), camera and computer.
- the system amplifies samples in a 96-well format on a thermocycler.
- laser-induced fluorescent signal is collected in real-time through fiber optics cables for all 96 wells, and detected at the CCD.
- the system includes software for running the instrument and for analyzing the data.
- 5′-Nuclease assay data are initially expressed as Ct, or the threshold cycle.
- Ct fluorescence values are recorded during every cycle and represent the amount of product amplified to that point in the amplification reaction. The point when the fluorescent signal is first recorded as statistically significant is the threshold cycle (C t ).
- RT-PCR is usually performed using an internal standard.
- the ideal internal standard is expressed at a constant level among different tissues, and is unaffected by the experimental treatment.
- RNAs most frequently used to normalize patterns of gene expression are mRNAs for the housekeeping genes glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) and ⁇ -actin.
- GPDH glyceraldehyde-3-phosphate-dehydrogenase
- ⁇ -actin glyceraldehyde-3-phosphate-dehydrogenase
- RT-PCR measures PCR product accumulation through a dual-labeled fluorigenic probe (i.e., TaqMan® probe).
- Real time PCR is compatible both with quantitative competitive PCR, where internal competitor for each target sequence is used for normalization, and with quantitative comparative PCR using a normalization gene contained within the sample, or a housekeeping gene for RT-PCR.
- quantitative competitive PCR where internal competitor for each target sequence is used for normalization
- quantitative comparative PCR using a normalization gene contained within the sample, or a housekeeping gene for RT-PCR.
- PCR amplified inserts of cDNA clones are applied to a substrate in a dense array.
- the microarrayed genes, immobilized on the microchip at 10,000 elements each, are suitable for hybridization under stringent conditions.
- Fluorescently labeled cDNA probes may be generated through incorporation of fluorescent nucleotides by reverse transcription of RNA extracted from tissues of interest. Labeled cDNA probes applied to the chip hybridize with specificity to each spot of DNA on the array. After stringent washing to remove non-specifically bound probes, the chip is scanned by confocal laser microscopy or by another detection method, such as a CCD camera.
- Quantitation of hybridization of each arrayed element allows for assessment of corresponding mRNA abundance.
- dual color fluorescence separately labeled cDNA probes generated from two sources of RNA are hybridized pairwise to the array. The relative abundance of the transcripts from the two sources corresponding to each specified gene is thus determined simultaneously.
- the miniaturized scale of the hybridization affords a convenient and rapid evaluation of the expression pattern for large numbers of genes. Such methods have been shown to have the sensitivity required to detect rare transcripts, which are expressed at a few copies per cell, and to reproducibly detect at least approximately two-fold differences in the expression levels (Schena et al., Proc. Natl. Acad. Sci. USA 93(2):106-149 (1996)).
- Microarray analysis can be performed by commercially available equipment, following manufacturer's protocols, such as by using the Affymetrix GenChip technology, or Incyte's microarray technology.
- microarray methods for large-scale analysis of gene expression makes it possible to search systematically for molecular markers of cancer classification and outcome prediction in a variety of tumor types.
- a common step in gene expression profiling by the RT-PCR and microarray techniques is the extraction of mRNA from biological samples.
- RNA isolation can be performed using purification kit, buffer set and protease from commercial manufacturers, such as Qiagen, according to the manufacturer's instructions. For example, total RNA from cells in culture can be isolated using Qiagen RNeasy mini-columns.
- RNA isolation kits include MasterPureTM Complete DNA and RNA Purification Kit (EPICENTRE®, Madison, Wis.), and Paraffin Block RNA Isolation Kit (Ambion, Inc.). Total RNA from tissue samples can be isolated using RNA Stat-60 (Tel-Test). RNA prepared from tumor can be isolated, for example, by cesium chloride density gradient centrifugation.
- RNA repair and/or amplification steps may be necessary before subjecting the RNA to any known expression gene profiling methods, including RT-PCR coupled with 5′ exonuclease of reporter probes (TaqMan® type assays), flap endonuclease assays (Cleavase and Invader type assays), oligonucleotide hybridization arrays, cDNA hybridization arrays, oligonucleotide ligation assays, 3′ single nucleotide extension assays and other assays designed to assess the abundance of specific mRNA sequences in a biological sample.
- RT-PCR coupled with 5′ exonuclease of reporter probes (TaqMan® type assays), flap endonuclease assays (Cleavase and Invader type assays), oligonucleotide hybridization arrays, cDNA hybridization arrays, oligonucleotide ligation assays, 3′ single nu
- RNA nucleic acid
- FPET paraffin-embedded tissue specimens
- FIG. 2 shows an example of RNA isolated from formalin-fixed, paraffin embedded (PFE) breast cancer samples that were archived from 1 to 17 years. RNA degradation progresses with archive storage time and results in RNA having an average size of about 100 bases after 17 years of storage. By comparison, intact mRNA has an average size of about 1800-2000 bases.
- PFE formalin-fixed, paraffin embedded
- RNA extraction of mRNA is typically followed by conversion to cDNA using the primer dependent enzyme reverse transcriptase (RT).
- RT reverse transcriptase
- FIG. 3 shows that intact mRNA can be efficiently profiled by TaqMan analysis using cDNA generated by RT and oligo dT priming.
- profiling of fixed, paraffin-embedded (FPET) or randomly degraded RNA (obtained by alkaline hydrolysis) by oligo dT primed cDNA synthesis is extremely inefficient as judged by the lower TaqMan signal (higher Ct) obtained relative to intact RNA.
- the signals from the intact RNA are on the average 500-1000-times greater than the corresponding signals from FPET RNA.
- FIG. 3 also shows that degraded RNA can be efficiently profiled using gene-specific primers (GSP). This indicates that most regions of the expressed genes are present in the randomly fragmented RNA in proportions expected for the intact mRNA. This result suggests that it should be possible to perform effective universal gene expression profiling on fragmented, e.g. FPET mRNA extracts.
- GSP gene-specific primers
- One recognition underlying the present invention is that the limited conversion of fragmented RNA to cDNA is due to the fact that in fragmented RNA, the 3′ end of a large proportion of RNA fragments is blocked and therefore not accessible to polyadenylation.
- RNA fragments ( ⁇ 100 bases) of three genes were generated by in vitro transcription (IVT), then pooled and polyadenylated. Polyadenylation was monitored by capillary electrophoresis on the Agilent 2100 BioAnalyzer.
- the FIG. 5 inset demonstrates that tailing of RNA with 0.1 and 0.2 units of E. coli polyA polymerase (EPAP) adds between 20 and 200 adenylates to the RNA.
- E. coli polyA polymerase E. coli polyA polymerase
- RNA was then reverse transcribed to cDNA using oligo dT priming and assayed by TaqMan analysis ( FIG. 5 ).
- polyadenylation of the RNA 0.2 EPAP/oligo-dT
- RNA any phosphatase, like calf alkaline phosphatase (CIP) or T4 polynucleotide kinase (PNK) can be used to remove 2′-3′ cyclic phosphates, 2′-monophosphates and 3′-monophosphates, generated typically on the 3′ terminal ribose moiety of degraded RNAs. This ensures efficient poly A addition by poly A polymerase to the 3′ terminus of the FPET RNA.
- CIP calf alkaline phosphatase
- PNK T4 polynucleotide kinase
- PNK which is also a 3′ phosphatase, catalyzes the hydrolysis of 3′-phosphoryl groups of deoxynucleoside 3′-monophosphates, deoxynucleoside 3′-, 5′diphosphates and of 3′-phosphoryl-polynucleotides.
- Other phosphatases like bacterial alkaline phosphatase, shrimp alkaline phosphatase, and derivatives thereof, can also be used to carry out such dephosphorylation reactions.
- the 3′ terminus now has a free 3′OH available.
- Polyadenylation or “poly A tailing” of mRNA or FPET mRNA after enzymatic reactions like dephosphorylation involves appending of adenylate molecules or poly (A) to the 3′ OH end of the RNA. In one embodiment, this is done using E. coli poly A polymerase. However, as will be understood by those skilled in the art, other poly A polymerases can also be used.
- FIG. 1 Three representative protocols (A, B and C) of the invention are illustrated in FIG. 1 .
- Processes A and B start with FPET RNA and involve 1) direct or indirect unblocking of the 3′ OH on the terminal nucleotide, 2) poly A tailing of the 3′end, 3) poly dT-primed double-strand cDNA synthesis with the incorporation of a T7 RNA polymerase promoter, and 4) RNA amplification by in vitro transcription.
- Process C starts with FPET RNA and involves 1) T7-(N)15 primed double-stranded cDNA synthesis with the incorporation of a T7 RNA polymerase promoter, and 2) RNA amplification by in vitro transcription.
- Protocol A involves a random primed (hexamers) cDNA synthesis that generates cDNA with a free 3′ OH on the terminal nucleotide of the FPET cDNA.
- the FPET cDNA is then tailed with Terminal Transferase (TdT) and dATP.
- TdT Terminal Transferase
- the poly dA-tailed cDNA is then converted to double-stranded DNA with DNA polymerase I (Klenow) and T7-(dT) 24 primer.
- This material is then amplified with T7 RNA polymerase and rNTPs to generate FPET RNA (+strand). This material is suitable for gene expression analysis by TaqMan®.
- the FPET RNA In order to be a suitable target for microarrays containing (+) strand probes, the FPET RNA needs to be converted to ( ⁇ ) strand cDNA in the presence of biotinylated dNTPs, random primers and RT. This material is now suitable for hybridization to microarrays in order to perform universal gene expression profiling. For microarrays containing double-stranded probes, this final step is not necessary. In this case, the IVT step should include biotin-rNTP's as in protocol B (below).
- Protocol B involves an unblocking of the 2′ OH and/or 3′OH of the 3′-terminal nucleotide of FPET RNA with polynucleotide kinase (PNK) or [pH2 treatment (0.01M HCl or maleic acid)] followed by calf intestinal alkaline phosphatase (CIP).
- PNK polynucleotide kinase
- CIP calf intestinal alkaline phosphatase
- the oligo dT primed cDNA can be directly used for gene expression analysis by TaqMan® analysis. This method is preferred if the amount of the FPET RNA is not limiting. If the amount of the FPET RNA is limiting, then the preferred method is to use the oligo dT-T7 primed cDNA, convert it to double-stranded DNA with DNA polymerase I and RNAse H and subsequently amplify it with T7 RNA polymerase and rNTPs.
- the oligo dT-T7 primed cDNA is converted to double-stranded DNA as above, and subsequently amplified with T7 RNA polymerase and biotinylated rNTPs.
- T7 RNA polymerase and biotinylated rNTPs.
- FIG. 11 An additional protocol of the invention is shown in FIG. 11 .
- the RT step is enhanced by using longer reverse primers as shown (10 bases, 20 bases and 30 bases) under otherwise normal RT conditions.
- the longer primers enable an increase in priming of the fragmented RNAs resulting in more cDNA target for the PCR step.
- the longer primers may aid in reverse transcription by bridging formalin-modified bases that would otherwise block enzymatic activity.
- An additional modification includes performing the initial two cycles of PCR at 50° C. This enables the amplification of more target cDNA due to the lower annealing temperature. Both of the above steps result in stronger gene expression signals.
- a rapid universal FPET RNA amplification procedure should greatly increase the number of genes that can be expression profiled and the number of studies that can be performed with typically limiting amounts of valuable clinical samples.
- the improvements are illustrated in FIG. 13 .
- the process starts with FPET RNA, generally 50-200 ng, and involves 1) unblocking of the 3′OH on the terminal nucleotide with PNK, 2) direct EPAP poly A tailing of the FPET RNA 3′ without cleanup from PNK step, 3) hybridization of polyadenylated FPET RNA to oligo dT-T7 RNA polymerase promoter sequences immobilized to beads followed by 4) cDNA synthesis with RT, 5) partial RNA degradation by RNAse H and second strand DNA synthesis with DNA polymerase I and 6) RNA amplification by in vitro transcription.
- An optional procedure for a second round of IVT is shown in step 7 (broken arrows).
- Another optional step, shown in step 2′ involves depletion of ribosomal rRNA fragments (dotted arrow).
- the beads used for nucleic acid hybridization can be commercially available microbeads, such as, for example, Dynal 2.8- ⁇ m magnetic streptavidin beads (M-280) or Dynabeads® MyOneTM Streptavidin (Dynal Biotech, Oslo, Norway). Streptavidin beads can be easily attached to 5′ or 3′ biotinylated nucleic acids. Bead-based immobilized oligo dT has been quite useful in purifying mRNA (Hornes, E. and Korsnes, L. (1990), Genet. Anal. Tech. Appl. 7:145; Jacobsen, K., Breivold, E. and Hornes, E. (1990) Nucleic Acids Res. 18:3669) and for subsequent aRNA amplification (Eberwine, J. (1995), Biotechniques 20:584).
- M-280 Dynal 2.8- ⁇ m magnetic streptavidin beads
- Dynabeads® MyOneTM Streptavidin Dynanal
- Example 1 the following methods were used.
- FIG. 2 shows an example of RNA isolated from formalin fixed, paraffin embedded (FPE) breast cancer samples that were archived from 1 to 17 years.
- RNA fragments complementary to amplicons for the genes HER2, GAPDH, and CYP were generated in two steps: 1) single-stranded DNA fragments complementary to the amplicons for these genes and containing a T7 RNA polymerase site on their 5′ end were synthesized (IDT, Coralville, Iowa) and amplified by PCR. 2) The PCR products were purified using CHROMA SPINTM TE-30 columns and cRNA was generated via the AmpliScribeTM T7 Transcription kit (Epicentre Technologies) and purified using CHROMA SPINTM DEPC-H 2 O 30 columns.
- the 3′-terminus of the FPET RNA was treated with either T4 polynucleotide kinase (PNK) or 0.01M HCl and calf alkaline phosphatase (CIP) to remove 2′-3′ cyclic phosphates, 2′-monophosphates and 3′-monophosphates.
- PNK polynucleotide kinase
- CIP calf alkaline phosphatase
- RNAse free H20 is extracted with 40 ⁇ l of phenol: CHCl 3 : IAA (25:24:1) pH 6.6 (Ambion, Inc., Austin, Tex.). After centrifugation at 14,000 ⁇ g for 1-2 min., the aqueous phase is removed, passed over a CHROMA SPINTM DEPC-H2O 30 column and volume reduced to 12.5 ⁇ L using a Savant speed vacuum.
- FPET RNA is incubated for 2 hrs in 10 mM HCl at 25° C.
- the FPET RNA is then passed over a CHROMA SPINTM DEPC-H2O 30 column as above and incubated with 10 units of CIP (New England Biolabs, Beverly, Mass.) for 30 min at 37° C. in 1 ⁇ NEBuffer 3 (10 mM NaCl, 5 mM Tris-HCl, pH 7.9, 1 mM MgCl 2 , 1 mM dithiothreitol) and 40 units of RNaseOUTTM (Invitrogen, Carlsbad, Calif.).
- RNAse free H2O is extracted with 40 ⁇ l of phenol: CHCl 3 : IAA (25:24:1) pH 6.6 (Ambion Inc., Austin, Tex.). After centrifugation at 14,000 ⁇ g for 1-2 min., the aqueous phase is removed, passed over a CHROMA SPINTM DEPC-H2O 30 column and volume reduced to 12.5 ⁇ L using a Savant speed vacuum.
- Reverse transcription was carried out using a SuperScriptTM First-Strand Synthesis Kit for RT-PCR (Invitrogen Corp., Carlsbad, Calif.). The reactions were carried out with total FPET RNA (3-50 ng/ ⁇ L) and either pooled gene specific primers (100 nM each) or oligo(dT) primers (25 ng/ ⁇ l) or oligo(dT)-T7 primers (0.25-5.0 ⁇ M).
- the extended primer reverse transcription the reaction was performed using the Orniscript Reverse Transcriptase for First-strand cDNA synthesis kit (Qiagen, Valencia, Calif.) as described.
- Total FPET RNA (3-50 ng/ ⁇ L) and pooled extended gene specific primers were used at concentrations of 3-50 ng/ ⁇ L and 100 nM (each primer), respectively.
- 1 st -strand cDNA synthesis products derived from 100-5000 ng FPET RNA were incubated at 16° C. (150 ⁇ L reaction volume) in 1 ⁇ second strand buffer [20 mM Tris-HCl, pH 6.9; 4.6 mM MgCl2; 90 mM KCl; 0.15 mM ⁇ -NAD + ; 10 mM (NH 4 ) 2 SO 4 ], 0.2 mM dNTP mix, 10 units DNA ligase, 40 units DNA polymerase 1, and 2 units RNase H (all reagents Invitrogen, Carlsbad, Calif.) for 2 hours. 9 units T4 DNA polymerase (NEBiolabs) were then added; reaction mix was incubated an additional 15 minutes. DNA was precipitated with 5M ammonium acetate and 100% ethanol, with 5 ⁇ g of glycogen as a carrier.
- the precipitated ds-DNA (from above) was resuspended in 8 ⁇ L nuclease-free H 2 O and an IVT reaction (20 ⁇ L total) was performed using MEGAscriptTM T7 kit (Ambion, Austin Tex.) and allowed to proceed for 4 hours at 37° C. Subsequently, reaction volume was increased to 40 ⁇ L with nuclease-free H2O and cRNA was precipitated with 3M sodium acetate and 100% ethanol. Precipitated cRNA was resuspended in 20-40 ⁇ L nuclease-free H2O.
- the TaqMan® reactions were performed in duplicate 5 ⁇ l reactions consisting of 1 ⁇ Universal PCR Master Mix and cDNA made from an equivalent of 1 ng of total RNA. Final primer and probe concentrations were 0.9 ⁇ M (each primer) and 0.2 ⁇ M, respectively. PCR cycling was carried out on the ABI Prism® 7900 as follows: 95° C. 10 minutes ⁇ 1 cycle, 95° C. 20 seconds, 60° C. 45 seconds ⁇ 40 cycles.
- the TaqMan® reactions were performed in triplicate 25 ⁇ l reactions consisting of 1 ⁇ PCR buffer A, 4 ⁇ M MgCl 2 , 0.2 ⁇ M dNTPs, 0.025 U/ ⁇ l AmpliTaq GoldTM DNA polymerase (Applied Biosystems, Foster City, Calif.), and cDNA made from an equivalent of 2.5 ng of total RNA. Final primer and probe concentrations are as above.
- PCR cycling was carried out on an ABI Prism® 7700 as above.
- PCR cycling was carried out on the ABI Prism® 7700 as follows: 95° C. 10 minutes ⁇ 1 cycle, 95° C. 20 seconds, 50° C. 2 minutes ⁇ 2 cycles, 95° C. 20 seconds, 60° C. 45 seconds ⁇ 38 cycles.
- RNA was treated with polynucleotide kinase (PNK) or calf intestinal alkaline phosphatase (CIP), enzymes with 2′-3′ cyclic phosphatase activity and 3′ phosphatase activity, respectively.
- Capillary electrophoretic [Agilent 2100] analysis of the treated FPET RNA suggested that treatment of the FPET RNA with PNK or CIP removed the blocking phosphates, as judged by a subtle decrease in the mobility of the enzyme-treated RNA relative to that of the untreated RNA ( FIG. 6A ). Decreased electrophoretic mobility was expected because removal of the charged phosphate group would have decreased the charge/mass ratio of the FPET RNA.
- FPET RNA was polyadenylated by EPAP following treatment with or without PNK or CIP, and the cDNA abundance was measured by TaqMan® RT-PCR.
- PNK FIG. 7
- CIP FIG. 8
- PNK FIG. 7
- CIP FIG. 8
- polyadenylation had very little effect on GSP primed cDNA synthesis.
- the GSP positive controls indicated that this universal priming method amplified cDNA 25-50% as effectively as the currently most effective priming method, GSP priming.
- cDNA was synthesized from polyadenylated FPET RNA (PNK and EPAP treated) and non-polyadenylated FPET RNA using either oligo dT primers or GSP primers, respectively.
- 96 pooled GSP primers were used and expression of 96 genes was analyzed by TaqMan® RT-PCR (using 1 ng FPET RNA/well, 384 wells; ABI Prism® 7900 instrument).
- the data shown in FIG. 9 demonstrate that polyadenylated FPET RNA was efficiently converted to cDNA (pA-dT) as judged by the similarity in Ct values to GSP-primed (pA_GSP1) cDNA.
- FIG. 10 (A-C) demonstrates the effect of polyadenylation and in vitro transcription (IVT) [T7 RNA polymerase amplification (Van Gelder et al., Proc. Natl. Acad. Sci. USA 87(5):1663-7 (1990)] on the expression of a 46 genes from three different RNA sources.
- FIG. 10A shows expression profiles from high quality intact RNA (Stratagene).
- IVT increased the average TaqMan signal of all 46 genes (see inset) ⁇ 6 fold when comparing cDNA generated by GSP primed RT (GSP; non-amplified control) and cDNA generated by oligo dT-T7 primed RT that was subsequently amplified by IVT (No EPAP IVT). Polyadenylation of the RNA prior to cDNA synthesis and IVT had no additional effect on the overall TaqMan signal (EPAP IVT-1 and IVT-2).
- FIG. 10B and 10C show gene expression profiles generated from moderately degraded FPET RNA (BioPath Placenta) and badly degraded FPET RNA (Clinomics 168), respectively.
- polyadenylation was a necessary step for IVT amplification of the RNA.
- the average TaqMan signals from duplicate experiments (EPAP IVT avg) were ⁇ 2.5 Cts lower (6 fold) than signals generated by IVT from non-polyadenylated RNA (No EPAP IVT).
- polyadenylation of degraded FPET RNA is a useful method to globally synthesize cDNA corresponding to each gene present in the sample. This cDNA can be used to further amplify gene signals accurately and reproducibly by IVT.
- FIG. 12 Another improvement for enhancement of gene expression signals is shown in FIG. 12 .
- the detection of six genes was enhanced as the primers were lengthened. Extending the primer lengths to 20-30 bases beyond the standard reverse primer (GSP) length, increased the gene expression signals from 10-15 fold. In addition, if the first two cycles of the subsequent PCR were performed at 50° C. rather than 60° C., the gene expression signals further increased several fold.
- GSP reverse primer
- MyOne Streptavidin-Coated Microspheres Dynal, 2 mL @ 10 mg/mL.
- Biotin-Eberwine Primer IDT, 100 pmol/uL stock (100 uM). 5′-Biotin-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTVN-3′ (SEQ ID NO: 1)
- T4 Polynucleotide Kinase (PNK): New England BioLabs, 2,500 units @ 10 U/ ⁇ L. Comes w/a 10 ⁇ reaction buffer.
- RNase Inhibitor Applied Biosystems, 20 U/ ⁇ L.
- Poly(A) Tailing Kit Ambion . Items used in kit— E. Coli poly(A) polymerase (EPAP) enzyme (2 U/ ⁇ L), 5 ⁇ reaction buffer, 10 mM ATP.
- E. Coli poly(A) polymerase (EPAP) enzyme (2 U/ ⁇ L), 5 ⁇ reaction buffer, 10 mM ATP.
- Superscript II RT enzyme Invitrogen, 200 U/ ⁇ L. Comes with 5 ⁇ RT buffer, which is used to create 1 ⁇ RT buffer for pre-RT washing step.
- DNA Polymerase I Invitrogen, 10 U/ ⁇ L.
- T4 DNA Polymerase Invitrogen, 5 U/ ⁇ L.
- Glycogen Ambion, 5 mg/mL.
- FPET RNA was incubated in 1 ⁇ PNK buffer (70 mM Tris-HCl pH 7.6, 10 mM MgCl 2 , 5 mM dithiothreitol), 1 U/ ⁇ l RNase Inhibitor (Applied Biosystems, Foster City, Calif.) and 1 U/ ⁇ l of PNK (NEBiolabs, Beverly, Mass.) at 37° C. for 30 min in a 20 ⁇ l reaction volume.
- 1 ⁇ PNK buffer 70 mM Tris-HCl pH 7.6, 10 mM MgCl 2 , 5 mM dithiothreitol
- RNase Inhibitor Applied Biosystems, Foster City, Calif.
- PNK N-labs, Beverly, Mass.
- the FPET RNA was directly polyadenylated by adding to the reaction mixture to a final concentration; 1 ⁇ EPAP buffer (Ambion, Austin, Tex.), 1 mM ATP, 1.5 U/ ⁇ l RNase Inhibitor and 0.025 U/ ⁇ l EPAP (Ambion, Austin, Tex.). The mixture was incubated at 37° C. for 15 min in a 40 ⁇ l reaction volume, then at 70° C. for 5 min.
- Dynabeads® MyOneTM Streptavidin (Dynal Biotech, Oslo, Norway) stock bead container was removed from 4° C. storage and vortexed vigorously to fully resuspend the beads.
- 40 ⁇ L (400 ⁇ g) beads were removed to a 0.5 mL microcentrifuge tube; spin beads down in a tabletop microcentrifuge ( ⁇ 5 sec) to collect liquid in bottom of tube. Avoid over-centrifuging tubes containing paramagnetic beads, as it will cause them to pellet and aggregate, which can reduce bead performance. Tubes were placed in a MPC-S magnetic rack (Dynal Biotech, Oslo, Norway) with the tube hinges facing the magnet and allow beads to collect against side of tube ( ⁇ 2 min).
- Tubes were opened without removing from rack; and the supernatant was pipetted off. Tubes were removed from rack; beads were washed by resuspending in 100 ⁇ L 1 ⁇ B&W buffer (5 mM Tris-HCl pH 7.3, 0.5 mM EDTA, 1M NaCl). Tubes were spinned down briefly to collect liquid, then placed in magnetic tube rack. Beads were allowed to collect against side of tube and supernatant was removed as above; and 1 ⁇ B&W buffer wash repeated for a total of two washes.
- 1 ⁇ B&W buffer 5 mM Tris-HCl pH 7.3, 0.5 mM EDTA, 1M NaCl
- FPET RNA For 200-300 ng of FPET RNA: During PNK/EPAP incubations, the previously prepared primer-bead solution was removed from 4° C. storage. The tube was flicked to resuspend beads and spinned down briefly to collect liquid. 20 ⁇ L (100 ⁇ g) of beads were aliquoted into a 0.5 mL tube and the tube placed on magnet for about 2 minutes. The supernatant was removed; beads were washed twice with 100 ⁇ L 1 ⁇ B&W Buffer. The final wash supernatant was removed during the 70° C. EPAP inactivation step. After the 70° C.
- Reverse transcription was carried out using a SuperScriptTM First-Strand Synthesis Kit for RT-PCR (Invitrogen Corp., Carlsbad, Calif.).
- FPET RNA For 200-300 ng of FPET RNA: Beads were washed once with 100 ⁇ L 1 ⁇ RT buffer (20 mM Tris-HCl pH 8.4, 50 mM KCl). Beads were resuspened in 20 ⁇ L RT reaction mix consisting of 1 ⁇ RT buffer, 5 mM MgCl 2 , 10 mM DTT, 0.5 mM dNTPs, 1 U/ ⁇ L RNase inhibitor, and 10 U/ ⁇ L SuperScript II RT and incubate at 42° C. on thermomixer (850 rpm) for 50 min.
- 1 ⁇ RT buffer 20 mM Tris-HCl pH 8.4, 50 mM KCl
- Beads were resuspened in 20 ⁇ L RT reaction mix consisting of 1 ⁇ RT buffer, 5 mM MgCl 2 , 10 mM DTT, 0.5 mM dNTPs, 1 U/ ⁇ L RNase inhibitor, and 10 U/
- Second strand cDNA reaction was removed from thermomixer and 130 ⁇ L of the following second strand reaction mix added: 1.15 ⁇ second strand buffer, 0.23 mM dNTP mix, 0.077 U/ ⁇ L DNA ligase, 0.31 U/ ⁇ L DNA polymerase I and 0.015 U/ ⁇ L RNase H. Flick tube to mix; spin down briefly. Incubate for 2 hrs at 16° C. on thermomixer (850 rpm).
- Second-strand reaction tube was removed from thermomixer; spinned down briefly and place on magnetic rack for about 2 minutes. Supernatant was removed and beads washed twice with 100 ⁇ L 1 ⁇ IVT wash buffer (400 mM Tris pH 7.3, 70 mM MgCl 2 , 100 mM NaCl, 20 mM spermidine.
- the MEGAScript -T7 IVT kit (Ambion, Austin Tex.) was used for in vitro transcription. Resuspend beads in 20 ⁇ L IVT master mix (prepared as described by Ambion) and flick tube to mix. Spin down briefly and incubate at 37° C. for 4 hrs on thermomixer (1000 rpm).
- the tube was vortexed and incubated @ ⁇ 20° C. from 1 hr to overnight.
- the tube was spinned down in a refrigerated Eppendorf centrifuge @ 14,000 rpm for 20 min (4° C.) to pellet cRNA.
- the supernatant was removed and 500 ⁇ L 70% ethanol solution was added to wash pellet.
- the tube was spinned down in a refrigerated Eppendorf centrifuge @ 14,000 rpm for 3 min (4° C.). With a pipet, as much alcohol was removed from the tube as possible, then the tube left (with top open) in a fume hood to allow remaining alcohol to evaporate (5-10 min).
- cRNA pellet was resuspended in 40 ⁇ L nuclease-free H 2 O.
- TaqMan® reactions were performed in duplicate 5 ⁇ l reactions consisting of 1 ⁇ Universal PCR Master Mix and 1 ng of cRNA. Final primer and probe concentrations were 0.9 ⁇ M (each primer) and 0.2 ⁇ M, respectively. PCR cycling was carried out on the ABI Prism® 7900 as follows: 95° C. 10 minutes ⁇ 1 cycle, 95° C. 20 seconds, 60° C. 45 seconds ⁇ 40 cycles.
- the 3′-terminus of the FPET RNA is treated with T4 polynucleotide kinase (PNK) to remove 2′-3′ cyclic phosphates, 2′-monophosphates and 3′-monophosphates.
- PNK polynucleotide kinase
- These various phosphate esters are typically found on the 3′ terminal ribose moiety of degraded RNAs and need to be removed to ensure efficient poly A addition to the 3′ terminus of the FPET RNA.
- the standard dephosphorylation step with PNK is terminated by addition of 20 ⁇ l of RNAse free H 2 O and extraction with 40 ⁇ l of phenol: CHCl 3 : IAA (25:24:1) pH 6.6 (Ambion, Inc., Austin, Tex.). After centrifugation at 14,000 ⁇ g for 1-2 min., the aqueous phase is removed, passed over a CHROMA SPINTM DEPC-H 2 O 30 column and volume reduced to 12.5 ⁇ L using a Savant speed vacuum. The RNA is now ready for the standard polyadenylation reaction with EPAP in a 20 ⁇ l volume.
- FIG. 15 shows a 47 gene panel profile of the amplified RNAs for conditions 2-5. All profiles showed a high concordance (R ⁇ 0.91) with unamplified RNA (SM) and standard treated RNA (condition 6). The no cleanup condition 5 gave the lowest average Ct (36.0) and the highest IVT yield (95.8 ⁇ g) and thus was adopted as the standard procedure for EPAP treatment (step 2, FIG. 13 ).
- Another improvement to the standard method of the present invention includes the hybridization of the polyadenylated FPET RNA to T7 promoter-oligo dT primers that are conjugated to magnetic polystyrene beads. This enables all subsequent enzymatic steps to be easily performed on a solid support with minimal cleanup steps. For instance, it eliminates the need for phenol-CHCl 3 extractions and spin column chromatography between reactions. The use of beads also lends itself to automated process that could greatly increase the throughput. In addition, archived, bead conjugated-cDNA libraries can be easily re-amplified to yield additional cRNA. FIG.
- FIG. 16 shows the 47 gene expression profile for placental cRNAs generated by the standard solution, non-bead based IVT method (free IVT) and cRNA generated by the solid phase, bead based IVT method (solid-phase IVT) outlined in FIG. 13 .
- non-amplified placental FPET RNA is also shown (SM).
- both IVT processes yielded cRNA that displayed a high concordance with untreated RNA (R ⁇ 0.94).
- R ⁇ 0.94 untreated RNA
- the traditional non-bead IVT method yielded 1.74 times more cRNA than the bead based IVT method, the average Ct was 0.74 higher.
- the bead based IVT method is nearly as efficient as the non-bead based method in terms of amplification and fidelity.
- both IVT methods do not achieve the same level of RT-PCR sensitivity (avg. Ct/mass RNA) as starting material when using equivalent amounts of RNA (1 ng/well), they still are achieving a 100-fold amplification of RNA after adjusting for the loss of sensitivity.
- FIG. 17 shows the 47 gene expression profile from 200 ng (condition 1) and 50 ng (conditions 2 and 3) of FPET RNA amplified by the bead-based protocol.
- condition 2 For the first 50 ng RNA amplification (condition 2), the ratio of RNA to bead mass and the reaction volumes of each step were identical to the standard 200 ng RNA amplification.
- the average Ct for the 50 ng volume-scaled amplification (condition 3) was equivalent to the 200 ng RNA amplification.
- the scaled down (1 ⁇ 4 vol) version was adopted as the 50 ng FPET RNA amplification procedure.
- FIG. 17 b shows the results of this experiment. Again, both 50 ng RNA amplications yielded approximately the same amount of cRNA, although 10-fold less than the 200 ng RNA amplification. In addition, all three secondary amplifications yielded about 1 ⁇ 3 as much RNA as their corresponding primary amplifications. A high level of fidelity was maintained between the three secondary amplifications (R ⁇ 0.95).
- the primary and secondary amplifications for each individual condition also maintained a high level of concordance (R ⁇ 0.97).
- the expression profiles for the condition 3 (FRA-1 ⁇ 4 vol: 50 ng/25 ug) primary and secondary IVTs are shown in FIG. 17 c.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Toys (AREA)
- Special Spraying Apparatus (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/020,946 US20050196782A1 (en) | 2003-12-23 | 2004-12-21 | Universal amplification of fragmented RNA |
US11/959,251 US8329398B2 (en) | 2003-12-23 | 2007-12-18 | Universal amplification of fragmented RNA |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53268403P | 2003-12-23 | 2003-12-23 | |
US11/020,946 US20050196782A1 (en) | 2003-12-23 | 2004-12-21 | Universal amplification of fragmented RNA |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/959,251 Continuation US8329398B2 (en) | 2003-12-23 | 2007-12-18 | Universal amplification of fragmented RNA |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050196782A1 true US20050196782A1 (en) | 2005-09-08 |
Family
ID=34738824
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/020,946 Abandoned US20050196782A1 (en) | 2003-12-23 | 2004-12-21 | Universal amplification of fragmented RNA |
US11/959,251 Active 2026-07-03 US8329398B2 (en) | 2003-12-23 | 2007-12-18 | Universal amplification of fragmented RNA |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/959,251 Active 2026-07-03 US8329398B2 (en) | 2003-12-23 | 2007-12-18 | Universal amplification of fragmented RNA |
Country Status (10)
Country | Link |
---|---|
US (2) | US20050196782A1 (de) |
EP (1) | EP1699936B1 (de) |
JP (1) | JP4718490B2 (de) |
AT (1) | ATE498022T1 (de) |
AU (1) | AU2004309396B2 (de) |
CA (1) | CA2551267C (de) |
DE (1) | DE602004031368D1 (de) |
ES (1) | ES2360113T3 (de) |
IL (1) | IL176522A (de) |
WO (1) | WO2005064019A2 (de) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050272075A1 (en) * | 2004-04-07 | 2005-12-08 | Nana Jacobsen | Novel methods for quantification of microRNAs and small interfering RNAs |
WO2007035742A2 (en) * | 2005-09-16 | 2007-03-29 | 454 Life Sciences Corporation | Cdna library preparation |
US20090123912A1 (en) * | 2005-01-25 | 2009-05-14 | Rosetta Inpharmatics Llc | Methods for quantitating small RNA molecules |
US20110111409A1 (en) * | 2009-11-10 | 2011-05-12 | Dominick Sinicropi | Methods for depleting rna from nucleic acid samples |
US20120009570A1 (en) * | 2006-03-01 | 2012-01-12 | Olivier Loudig | Restoration of Nucleic Acid From Degraded or Formalin-Fixed and Paraffin-Embedded Tissue and Uses Thereof |
US20120202198A1 (en) * | 2006-08-14 | 2012-08-09 | Qiagen Gmbh | Process for the synthesis of a cdna in a sample in an enzymatic reaction |
WO2013133680A1 (ko) * | 2012-03-09 | 2013-09-12 | (주)바이오니아 | 핫스타트 역전사반응 또는 핫스타트 역전사 중합효소 연쇄반응용 조성물 |
US9376711B2 (en) | 2011-07-13 | 2016-06-28 | Qiagen Mansfield, Inc. | Multimodal methods for simultaneous detection and quantification of multiple nucleic acids in a sample |
US9464106B2 (en) | 2002-10-21 | 2016-10-11 | Exiqon A/S | Oligonucleotides useful for detecting and analyzing nucleic acids of interest |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7361465B2 (en) * | 2004-09-07 | 2008-04-22 | Applera Corporation | Methods and compositions for tailing and amplifying RNA |
US7550264B2 (en) * | 2005-06-10 | 2009-06-23 | Datascope Investment Corporation | Methods and kits for sense RNA synthesis |
WO2009021757A1 (de) * | 2007-08-13 | 2009-02-19 | Qiagen Gmbh | Verfahren zur synthese einer cdna in einer probe in einer enzymatischen reaktion |
JP4807470B2 (ja) | 2009-12-16 | 2011-11-02 | 東レ株式会社 | Rnaの解析方法 |
EP2484760B1 (de) * | 2010-04-22 | 2015-10-14 | Toray Industries, Inc. | Verfahren zur herstellung von a-rna. |
US9422601B2 (en) | 2011-12-15 | 2016-08-23 | Samsung Electronics Co., Ltd. | Method of determining a ratio of RNA species in a sample |
WO2016092062A1 (en) * | 2014-12-11 | 2016-06-16 | Qiagen Gmbh | Method for improving the efficiency of cdna generation |
US10696994B2 (en) | 2018-09-28 | 2020-06-30 | Bioo Scientific Corporation | Size selection of RNA using poly(A) polymerase |
EP3874059A1 (de) * | 2018-10-29 | 2021-09-08 | Koninklijke Nederlandse Akademie van Wetenschappen | Volllängen-rna-sequenzierung einer einzelzelle |
Citations (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4699877A (en) * | 1982-11-04 | 1987-10-13 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US5015568A (en) * | 1986-07-09 | 1991-05-14 | The Wistar Institute | Diagnostic methods for detecting lymphomas in humans |
US5200313A (en) * | 1983-08-05 | 1993-04-06 | Miles Inc. | Nucleic acid hybridization assay employing detectable anti-hybrid antibodies |
US5202429A (en) * | 1986-07-09 | 1993-04-13 | The Wistar Institute | DNA molecules having human BCL-2 gene sequences |
USRE35491E (en) * | 1982-11-04 | 1997-04-08 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
US5670325A (en) * | 1996-08-14 | 1997-09-23 | Exact Laboratories, Inc. | Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample |
US5741650A (en) * | 1996-01-30 | 1998-04-21 | Exact Laboratories, Inc. | Methods for detecting colon cancer from stool samples |
US5830753A (en) * | 1994-09-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. |
US5858678A (en) * | 1994-08-02 | 1999-01-12 | St. Louis University | Apoptosis-regulating proteins |
US5861278A (en) * | 1996-11-01 | 1999-01-19 | Genetics Institute, Inc. | HNF3δ compositions |
US5928870A (en) * | 1997-06-16 | 1999-07-27 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
US5952178A (en) * | 1996-08-14 | 1999-09-14 | Exact Laboratories | Methods for disease diagnosis from stool samples |
US5952179A (en) * | 1996-05-23 | 1999-09-14 | St. Louis University Health Sciences Center | Screens for mutations in the anti-proliferation domain of human Bcl-2 |
US5962312A (en) * | 1995-12-18 | 1999-10-05 | Sugen, Inc. | Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders |
US5985553A (en) * | 1986-03-05 | 1999-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | erbB-2 gene segments, probes, recombinant DNA and kits for detection |
US6020137A (en) * | 1996-08-14 | 2000-02-01 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
US6100029A (en) * | 1996-08-14 | 2000-08-08 | Exact Laboratories, Inc. | Methods for the detection of chromosomal aberrations |
US6114152A (en) * | 1997-12-12 | 2000-09-05 | The Regents Of The University Of California | Methods for making nucleic acids |
US6143529A (en) * | 1996-08-14 | 2000-11-07 | Exact Laboratories, Inc. | Methods for improving sensitivity and specificity of screening assays |
US6146828A (en) * | 1996-08-14 | 2000-11-14 | Exact Laboratories, Inc. | Methods for detecting differences in RNA expression levels and uses therefor |
US6171798B1 (en) * | 1998-03-27 | 2001-01-09 | Affymetrix, Inc. | P53-regulated genes |
US6203993B1 (en) * | 1996-08-14 | 2001-03-20 | Exact Science Corp. | Methods for the detection of nucleic acids |
US6207401B1 (en) * | 1995-12-18 | 2001-03-27 | Sugen, Inc. | Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders |
US6245523B1 (en) * | 1996-11-20 | 2001-06-12 | Yale University | Survivin, a protein that inhibits cellular apoptosis, and its modulation |
US6248535B1 (en) * | 1999-12-20 | 2001-06-19 | University Of Southern California | Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens |
US6271002B1 (en) * | 1999-10-04 | 2001-08-07 | Rosetta Inpharmatics, Inc. | RNA amplification method |
US6322986B1 (en) * | 2000-01-18 | 2001-11-27 | Albany Medical College | Method for colorectal cancer prognosis and treatment selection |
US20020004491A1 (en) * | 1999-09-10 | 2002-01-10 | Jiangchun Xu | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US20020009736A1 (en) * | 2000-03-31 | 2002-01-24 | Eugenia Wang | Microarrays to screen regulatory genes |
US6351712B1 (en) * | 1998-12-28 | 2002-02-26 | Rosetta Inpharmatics, Inc. | Statistical combining of cell expression profiles |
US20020039764A1 (en) * | 1999-03-12 | 2002-04-04 | Rosen Craig A. | Nucleic, acids, proteins, and antibodies |
US6414134B1 (en) * | 1988-12-22 | 2002-07-02 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
US20020160395A1 (en) * | 2001-01-12 | 2002-10-31 | Altieri Dario C. | Detection of survivin in the biological fluids of cancer patients |
US20030073112A1 (en) * | 2000-01-13 | 2003-04-17 | Jing Zhang | Universal nucleic acid amplification system for nucleic acids in a sample |
US20030104499A1 (en) * | 2001-03-12 | 2003-06-05 | Monogen, Inc. | Cell-based detection and differentiation of lung cancer |
US6582919B2 (en) * | 2001-06-11 | 2003-06-24 | Response Genetics, Inc. | Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates |
US6602670B2 (en) * | 2000-12-01 | 2003-08-05 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
US20030165952A1 (en) * | 2000-07-21 | 2003-09-04 | Sten Linnarsson | Method and an alggorithm for mrna expression analysis |
US6618679B2 (en) * | 2000-01-28 | 2003-09-09 | Althea Technologies, Inc. | Methods for analysis of gene expression |
US6620606B2 (en) * | 1997-06-26 | 2003-09-16 | Incyte Corporation | Human cathepsin |
US20030198970A1 (en) * | 1998-06-06 | 2003-10-23 | Genostic Pharma Limited | Genostics |
US20030198972A1 (en) * | 2001-12-21 | 2003-10-23 | Erlander Mark G. | Grading of breast cancer |
US20030219771A1 (en) * | 2001-11-09 | 2003-11-27 | Michael Bevilacqua | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
US20030229455A1 (en) * | 1999-06-28 | 2003-12-11 | Bevilacqua Michael P. | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles |
US20040009489A1 (en) * | 2001-09-28 | 2004-01-15 | Golub Todd R. | Classification of lung carcinomas using gene expression analysis |
US6696558B2 (en) * | 1998-09-09 | 2004-02-24 | The Burnham Institute | Bag proteins and nucleic acid molecules encoding them |
US6750013B2 (en) * | 1999-12-02 | 2004-06-15 | Protein Design Labs, Inc. | Methods for detection and diagnosing of breast cancer |
US20040126775A1 (en) * | 2001-01-12 | 2004-07-01 | Altieri Dario C. | Detection of survivin in the biological fluids of cancer patients |
US20040133352A1 (en) * | 1999-06-28 | 2004-07-08 | Michael Bevilacqua | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE56509B1 (en) | 1982-11-04 | 1991-08-28 | Univ California | Methods for oncogenic detection |
JPH04501353A (ja) * | 1988-07-26 | 1992-03-12 | ジエネラブス・テクノロジーズ・インコーポレイテツド | Rna及びdna増幅法 |
US7172864B1 (en) * | 1993-11-01 | 2007-02-06 | Nanogen | Methods for electronically-controlled enzymatic reactions |
WO1999002714A1 (en) | 1997-07-07 | 1999-01-21 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
AU3246200A (en) | 1999-02-25 | 2000-09-14 | Boris Bilynsky | Nucleic acid molecules associated with melanoma and thyroid tumors |
AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
US6326148B1 (en) | 1999-07-12 | 2001-12-04 | The Regents Of The University Of California | Detection of copy number changes in colon cancer |
WO2001025250A1 (en) | 1999-10-06 | 2001-04-12 | The Regents Of The University Of California | Differentially expressed genes associated with her-2/neu overexpression |
CA2490853A1 (en) | 1999-12-01 | 2001-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030022318A1 (en) * | 2000-01-25 | 2003-01-30 | Epiclone, Inc. | Method for thermocycling amplification of nucleic acid sequences and the generation of related peptides thereof |
WO2001055319A2 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Endocrine related nucleic acids, proteins and antibodies |
AU4592601A (en) | 2000-03-21 | 2001-10-03 | Millennium Predictive Medicine | Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer |
WO2002000677A1 (en) | 2000-06-07 | 2002-01-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
AU2001277202A1 (en) | 2000-07-26 | 2002-02-05 | Applied Genomics, Inc. | Bstp-ras/rerg protein and related reagents and methods of use thereof |
WO2002008765A2 (en) | 2000-07-26 | 2002-01-31 | Stanford University | Basal cell markers in breast cancer and uses thereof |
AU2001278011A1 (en) | 2000-07-26 | 2002-02-05 | Applied Genomics, Inc. | Bstp-ecg1 protein and related reagents and methods of use thereof |
US7795232B1 (en) | 2000-08-25 | 2010-09-14 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
EP1353947A2 (de) | 2000-12-08 | 2003-10-22 | Ipsogen | Erstellung von genexpressionsprofilen bei primärem brustkrebs unter verwendung von arrays mit putativ involvierten genen |
AU2002255478A1 (en) | 2001-01-10 | 2002-09-12 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
WO2002059377A2 (en) | 2001-01-24 | 2002-08-01 | Protein Design Labs | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
JP2005500832A (ja) | 2001-06-18 | 2005-01-13 | ロゼッタ・インファーマティクス・インコーポレーテッド | 乳癌患者の診断および予後 |
WO2003011897A1 (en) | 2001-07-27 | 2003-02-13 | The Regents Of The University Of California | Modulation of heregulin and her3 interaction |
EP2241636A1 (de) * | 2002-03-13 | 2010-10-20 | Genomic Health, Inc. | Genexpressionsprofilierung in einer Biopsie unterzogenem Tumorgewebe |
WO2003083096A2 (en) | 2002-03-28 | 2003-10-09 | Qlt Inc. | Cancer associated protein kinases and their uses |
EP1900827A3 (de) | 2002-05-21 | 2008-04-16 | Bayer HealthCare AG | Verfahren und Zusammensetzungen zur Vorhersage, Diagnose, Prognose, Verhinderung und Behandlung maligner Neoplasien |
ATE420975T1 (de) * | 2003-03-21 | 2009-01-15 | Mds Analytical Technologies Us | Methode zur linearen nicht-selektiven amplifikation von nukleinsäuren |
-
2004
- 2004-12-21 US US11/020,946 patent/US20050196782A1/en not_active Abandoned
- 2004-12-21 CA CA2551267A patent/CA2551267C/en active Active
- 2004-12-21 WO PCT/US2004/043163 patent/WO2005064019A2/en active Application Filing
- 2004-12-21 ES ES04815264T patent/ES2360113T3/es active Active
- 2004-12-21 EP EP04815264A patent/EP1699936B1/de active Active
- 2004-12-21 AU AU2004309396A patent/AU2004309396B2/en active Active
- 2004-12-21 JP JP2006547324A patent/JP4718490B2/ja active Active
- 2004-12-21 DE DE602004031368T patent/DE602004031368D1/de active Active
- 2004-12-21 AT AT04815264T patent/ATE498022T1/de not_active IP Right Cessation
-
2006
- 2006-06-22 IL IL176522A patent/IL176522A/en active IP Right Grant
-
2007
- 2007-12-18 US US11/959,251 patent/US8329398B2/en active Active
Patent Citations (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4699877A (en) * | 1982-11-04 | 1987-10-13 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
USRE35491E (en) * | 1982-11-04 | 1997-04-08 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
US5200313A (en) * | 1983-08-05 | 1993-04-06 | Miles Inc. | Nucleic acid hybridization assay employing detectable anti-hybrid antibodies |
US5985553A (en) * | 1986-03-05 | 1999-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | erbB-2 gene segments, probes, recombinant DNA and kits for detection |
US5015568A (en) * | 1986-07-09 | 1991-05-14 | The Wistar Institute | Diagnostic methods for detecting lymphomas in humans |
US5202429A (en) * | 1986-07-09 | 1993-04-13 | The Wistar Institute | DNA molecules having human BCL-2 gene sequences |
US5459251A (en) * | 1986-07-09 | 1995-10-17 | The Wistar Institute | DNA molecules having human bcl-2 gene sequences |
US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US6414134B1 (en) * | 1988-12-22 | 2002-07-02 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
US5858678A (en) * | 1994-08-02 | 1999-01-12 | St. Louis University | Apoptosis-regulating proteins |
US5830753A (en) * | 1994-09-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. |
US6716575B2 (en) * | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
US6207401B1 (en) * | 1995-12-18 | 2001-03-27 | Sugen, Inc. | Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders |
US5962312A (en) * | 1995-12-18 | 1999-10-05 | Sugen, Inc. | Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders |
US5741650A (en) * | 1996-01-30 | 1998-04-21 | Exact Laboratories, Inc. | Methods for detecting colon cancer from stool samples |
US5952179A (en) * | 1996-05-23 | 1999-09-14 | St. Louis University Health Sciences Center | Screens for mutations in the anti-proliferation domain of human Bcl-2 |
US20030180791A1 (en) * | 1996-05-23 | 2003-09-25 | St. Louis University | Anti-proliferation domain of human Bcl-2 and DNA encoding the same |
US6207452B1 (en) * | 1996-05-23 | 2001-03-27 | St. Louis University Health Sciences Center | Antibody of the anti-proliferation domain of human Bcl-2 |
US6143529A (en) * | 1996-08-14 | 2000-11-07 | Exact Laboratories, Inc. | Methods for improving sensitivity and specificity of screening assays |
US5952178A (en) * | 1996-08-14 | 1999-09-14 | Exact Laboratories | Methods for disease diagnosis from stool samples |
US5670325A (en) * | 1996-08-14 | 1997-09-23 | Exact Laboratories, Inc. | Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample |
US6146828A (en) * | 1996-08-14 | 2000-11-14 | Exact Laboratories, Inc. | Methods for detecting differences in RNA expression levels and uses therefor |
US6214558B1 (en) * | 1996-08-14 | 2001-04-10 | Exact Laboratories, Inc. | Methods for the detection of chromosomal aberrations |
US6203993B1 (en) * | 1996-08-14 | 2001-03-20 | Exact Science Corp. | Methods for the detection of nucleic acids |
US6100029A (en) * | 1996-08-14 | 2000-08-08 | Exact Laboratories, Inc. | Methods for the detection of chromosomal aberrations |
US6020137A (en) * | 1996-08-14 | 2000-02-01 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
US5861278A (en) * | 1996-11-01 | 1999-01-19 | Genetics Institute, Inc. | HNF3δ compositions |
US6245523B1 (en) * | 1996-11-20 | 2001-06-12 | Yale University | Survivin, a protein that inhibits cellular apoptosis, and its modulation |
US6943150B1 (en) * | 1996-11-20 | 2005-09-13 | Yale University | Survivin, a protein that inhibits cellular apoptosis and its modulation |
US6800737B2 (en) * | 1996-11-20 | 2004-10-05 | Yale University | Survivin, a protein that inhibits cellular apoptosis, and its modulation |
US5928870A (en) * | 1997-06-16 | 1999-07-27 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
US6620606B2 (en) * | 1997-06-26 | 2003-09-16 | Incyte Corporation | Human cathepsin |
US6114152A (en) * | 1997-12-12 | 2000-09-05 | The Regents Of The University Of California | Methods for making nucleic acids |
US6171798B1 (en) * | 1998-03-27 | 2001-01-09 | Affymetrix, Inc. | P53-regulated genes |
US20030198970A1 (en) * | 1998-06-06 | 2003-10-23 | Genostic Pharma Limited | Genostics |
US6696558B2 (en) * | 1998-09-09 | 2004-02-24 | The Burnham Institute | Bag proteins and nucleic acid molecules encoding them |
US6351712B1 (en) * | 1998-12-28 | 2002-02-26 | Rosetta Inpharmatics, Inc. | Statistical combining of cell expression profiles |
US20020039764A1 (en) * | 1999-03-12 | 2002-04-04 | Rosen Craig A. | Nucleic, acids, proteins, and antibodies |
US20040133352A1 (en) * | 1999-06-28 | 2004-07-08 | Michael Bevilacqua | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
US20030229455A1 (en) * | 1999-06-28 | 2003-12-11 | Bevilacqua Michael P. | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles |
US20020004491A1 (en) * | 1999-09-10 | 2002-01-10 | Jiangchun Xu | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US6271002B1 (en) * | 1999-10-04 | 2001-08-07 | Rosetta Inpharmatics, Inc. | RNA amplification method |
US6750013B2 (en) * | 1999-12-02 | 2004-06-15 | Protein Design Labs, Inc. | Methods for detection and diagnosing of breast cancer |
US6248535B1 (en) * | 1999-12-20 | 2001-06-19 | University Of Southern California | Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens |
US20030073112A1 (en) * | 2000-01-13 | 2003-04-17 | Jing Zhang | Universal nucleic acid amplification system for nucleic acids in a sample |
US6322986B1 (en) * | 2000-01-18 | 2001-11-27 | Albany Medical College | Method for colorectal cancer prognosis and treatment selection |
US6618679B2 (en) * | 2000-01-28 | 2003-09-09 | Althea Technologies, Inc. | Methods for analysis of gene expression |
US20020009736A1 (en) * | 2000-03-31 | 2002-01-24 | Eugenia Wang | Microarrays to screen regulatory genes |
US20030165952A1 (en) * | 2000-07-21 | 2003-09-04 | Sten Linnarsson | Method and an alggorithm for mrna expression analysis |
US6602670B2 (en) * | 2000-12-01 | 2003-08-05 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
US20040126775A1 (en) * | 2001-01-12 | 2004-07-01 | Altieri Dario C. | Detection of survivin in the biological fluids of cancer patients |
US20020160395A1 (en) * | 2001-01-12 | 2002-10-31 | Altieri Dario C. | Detection of survivin in the biological fluids of cancer patients |
US20030104499A1 (en) * | 2001-03-12 | 2003-06-05 | Monogen, Inc. | Cell-based detection and differentiation of lung cancer |
US6582919B2 (en) * | 2001-06-11 | 2003-06-24 | Response Genetics, Inc. | Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates |
US20040009489A1 (en) * | 2001-09-28 | 2004-01-15 | Golub Todd R. | Classification of lung carcinomas using gene expression analysis |
US20030219771A1 (en) * | 2001-11-09 | 2003-11-27 | Michael Bevilacqua | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
US20030198972A1 (en) * | 2001-12-21 | 2003-10-23 | Erlander Mark G. | Grading of breast cancer |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9464106B2 (en) | 2002-10-21 | 2016-10-11 | Exiqon A/S | Oligonucleotides useful for detecting and analyzing nucleic acids of interest |
US8383344B2 (en) * | 2004-04-07 | 2013-02-26 | Exiqon A/S | Methods for quantification of microRNAs and small interfering RNAs |
US20110076675A1 (en) * | 2004-04-07 | 2011-03-31 | Exiqon A/S | Novel methods for quantification of micrornas and small interfering rnas |
US8192937B2 (en) | 2004-04-07 | 2012-06-05 | Exiqon A/S | Methods for quantification of microRNAs and small interfering RNAs |
US20050272075A1 (en) * | 2004-04-07 | 2005-12-08 | Nana Jacobsen | Novel methods for quantification of microRNAs and small interfering RNAs |
US20090123912A1 (en) * | 2005-01-25 | 2009-05-14 | Rosetta Inpharmatics Llc | Methods for quantitating small RNA molecules |
US20070117121A1 (en) * | 2005-09-16 | 2007-05-24 | Hutchison Stephen K | cDNA library preparation |
WO2007035742A3 (en) * | 2005-09-16 | 2007-08-02 | 454 Life Sciences Corp | Cdna library preparation |
WO2007035742A2 (en) * | 2005-09-16 | 2007-03-29 | 454 Life Sciences Corporation | Cdna library preparation |
US20120009570A1 (en) * | 2006-03-01 | 2012-01-12 | Olivier Loudig | Restoration of Nucleic Acid From Degraded or Formalin-Fixed and Paraffin-Embedded Tissue and Uses Thereof |
US8497067B2 (en) * | 2006-03-01 | 2013-07-30 | Albert Einstein College Of Medicine Of Yeshiva University | Restoration of nucleic acid from degraded or formalin-fixed and paraffin-embedded tissue and uses thereof |
US9217173B2 (en) * | 2006-08-14 | 2015-12-22 | Qiagen Gmbh | Method of polyadenylation and CDNA synthesis in a single reaction |
US20120202198A1 (en) * | 2006-08-14 | 2012-08-09 | Qiagen Gmbh | Process for the synthesis of a cdna in a sample in an enzymatic reaction |
US20110111409A1 (en) * | 2009-11-10 | 2011-05-12 | Dominick Sinicropi | Methods for depleting rna from nucleic acid samples |
US9005891B2 (en) * | 2009-11-10 | 2015-04-14 | Genomic Health, Inc. | Methods for depleting RNA from nucleic acid samples |
US9902991B2 (en) | 2009-11-10 | 2018-02-27 | Genomic Health, Inc. | Methods for depleting RNA from nucleic acid samples |
US20180208968A1 (en) * | 2009-11-10 | 2018-07-26 | Genomic Health, Inc. | Methods for depleting rna from nucleic acid samples |
US11149297B2 (en) | 2009-11-10 | 2021-10-19 | Genomic Health, Inc. | Methods for depleting RNA from nucleic acid samples |
US9376711B2 (en) | 2011-07-13 | 2016-06-28 | Qiagen Mansfield, Inc. | Multimodal methods for simultaneous detection and quantification of multiple nucleic acids in a sample |
WO2013133680A1 (ko) * | 2012-03-09 | 2013-09-12 | (주)바이오니아 | 핫스타트 역전사반응 또는 핫스타트 역전사 중합효소 연쇄반응용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
JP4718490B2 (ja) | 2011-07-06 |
KR20070000438A (ko) | 2007-01-02 |
IL176522A (en) | 2012-06-28 |
IL176522A0 (en) | 2006-10-05 |
CA2551267C (en) | 2012-05-01 |
AU2004309396B2 (en) | 2010-05-13 |
EP1699936B1 (de) | 2011-02-09 |
AU2004309396A1 (en) | 2005-07-14 |
WO2005064019A3 (en) | 2005-09-15 |
EP1699936A2 (de) | 2006-09-13 |
DE602004031368D1 (de) | 2011-03-24 |
CA2551267A1 (en) | 2005-07-14 |
ATE498022T1 (de) | 2011-02-15 |
WO2005064019A2 (en) | 2005-07-14 |
ES2360113T3 (es) | 2011-06-01 |
US20090042192A1 (en) | 2009-02-12 |
JP2007515964A (ja) | 2007-06-21 |
US8329398B2 (en) | 2012-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8329398B2 (en) | Universal amplification of fragmented RNA | |
US11149297B2 (en) | Methods for depleting RNA from nucleic acid samples | |
EP2464755B1 (de) | Verfahren und kits zur 3'-enden-markierung von rna | |
EP3192877B1 (de) | Vesikulärer adapter und verwendungen davon in der nukleinsäurebibliothekkonstruktion und -sequenzierung | |
EP3169799B1 (de) | Halbzufällige strichcodes zur nukleinsäureanalyse | |
US10017761B2 (en) | Methods for preparing cDNA from low quantities of cells | |
US8512956B2 (en) | Method for clonal amplification | |
EP0592626B1 (de) | Methode um mrna zu klonieren | |
EP2794926B1 (de) | Verfahren zur herstellung kleiner rna-bibliotheken und ihre verwendung zur expressionsprofilierung von ziel-rnas | |
US20050153333A1 (en) | Selective terminal tagging of nucleic acids | |
EP2247727A2 (de) | Verfahren zur archivierung und klonalen expansion | |
WO2014134320A1 (en) | Methods, compositions and systems for the analysis of nucleic acid molecules | |
WO2004085681A2 (en) | Global linear non-biased nucleic acid amplification | |
KR20060136408A (ko) | 단편화 rna의 범용적 증폭 | |
US20080096198A1 (en) | Primer Having Promoter Region Added Thereto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GENOMIC HEALTH, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIEFFER, MICHAEL C.;HOYT, KENNETH W.;REEL/FRAME:015974/0491;SIGNING DATES FROM 20050315 TO 20050323 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |